# Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

> **NCT04537793** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 83 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** ELX/TEZ/IVA
- **DRUG:** IVA

## Key facts

- **NCT ID:** NCT04537793
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-19
- **Primary completion:** 2022-06-03
- **Final completion:** 2022-06-03
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04537793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04537793, "Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04537793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*